Neeraj Agarwal: Breaking news: Glad to report the news from ph3 Contact-2 trial Cabozantinib + atezolizumab significantly improved outcomes in mCRPC prostate cancer.

Neeraj Agarwal stated on Twitter:

“Breaking news: Glad to report the news from ph3 Contact-2 trial Cabozantinib + atezolizumab significantly improved outcomes in mCRPC prostate cancer. Trial description from ASCO TIP abstract Press release: http://shorturl.at/cCQY4”

Source: Neeraj Agarwal/Twitter

Neeraj Agarwal is a Professor of medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI. Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.